T-Therapeutics Raises $133M Series B to Push TCR Therapies Into Clinics
Cambridge-based T-Therapeutics closed a $133 million oversubscribed Series B to take its TCR-CD3 bispecific programs in cancer and autoimmunity to clinical proof of concept.
Topic
Clinical Development
Topic
Clinical Development
Biograil Raises €20 Million to Move Oral Drug Platform Toward Trials
Copenhagen-based Biograil raised €20 million to advance its capsule-based BIONDD oral delivery platform through preclinical work…